ASCO 2026 | Future directions for EGFR-targeted immunotherapy in HNSCC
Jacob Thomas, MD, University of Southern California, Los Angeles, CA, discusses the potential of the Phase II study Phase II study (NCT05172258) in relation to current EGFR targeting therapies and checkpoint inhibitors in head and neck squamous cell carcinoma (HNSCC), noting that several promising studies may lead to FDA approvals in the coming years. The next steps for the study involve identifying a specific subpopulation that may derive the most benefit from this combination and further developing it from there. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There’s many great contenders out there right now, especially EGFR targeting therapies combining with checkpoint inhibitors. So where my study might fit with that is a great question. There’s a lot of promising, a lot of these studies are promising. We may see an FDA approval in the coming years. So I think what’s next for my study is, as I said, identifying a subpopulation perhaps that may benefit the most from this combination and then further developing it from there...
There’s many great contenders out there right now, especially EGFR targeting therapies combining with checkpoint inhibitors. So where my study might fit with that is a great question. There’s a lot of promising, a lot of these studies are promising. We may see an FDA approval in the coming years. So I think what’s next for my study is, as I said, identifying a subpopulation perhaps that may benefit the most from this combination and then further developing it from there.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
